A phase I, pharmacokinetic and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors

PURPOSE: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances anti-proliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib. We evaluated this combination in advanced NSCLC and head-and-neck (H&N) cancer patients. EXPERIMENTAL DESIGN: Eligibl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gray, Jhanelle E., Haura, Eric, Chiappori, Alberto, Tanvetyanon, Tawee, Williams, Charles C., Pinder-Schenck, Mary, Kish, Julie A., Kreahling, Jenny, Lush, Richard, Neuger, Anthony, Tetteh, Leticia, Akar, Angela, Zhao, Xiuhua, Schell, Michael J., Bepler, Gerold, Altiok, Soner
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4051132/
https://ncbi.nlm.nih.gov/pubmed/24429877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2235
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak